Australia's TGA launches first major shake-up in 20 years
This article was originally published in RAJ Devices
The Australian Therapeutic Goods Administration has been restructured in an effort to better support the delivery of appropriate, consistent, effective and efficient regulation1,2. This is the first comprehensive review of the agency that has taken place since it was set up more than 20 years ago.
You may also be interested in...
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
In the second segment of a two-part article on transparency provisions for the new EU clinical trial portal, a senior Merck executive explains how the company will ensure that commercially sensitive information and personal data in its clinical trial applications are not made public.
In the first of a two-part article on transparency provisions for the new EU clinical trial portal, the Pink Sheet reports on aspects that sponsors must consider to protect commercially confidential information in their clinical trial applications. The second article will look at the approach taken by Merck and discuss outstanding hot topics in relation to transparency and CTIS.